

## §7.5

and a proportionate share of management and administrative costs), and the costs of particular ingredients. Charges may vary over time and between different biological standards or biological preparations, depending upon the cost of ingredients and the complexity of production. An up-to-date schedule of charges is available from the Biological Products Branch, Center for Infectious Diseases, Centers for Disease Control, 1600 Clifton Road, Atlanta, Georgia 30333.

### §7.5 Payment procedures.

The requester may obtain information on terms of payment and a fee schedule by writing the "Centers for Disease Control," Financial Management Office, Buckhead Facility, Room 200, Centers for Disease Control, 1600 Clifton Road, Atlanta, Georgia 30333.

### §7.6 Exemptions.

State and local health departments, governmental institutions (e.g., State hospitals and universities), the World Health Organization, and ministries of health of foreign governments may be exempted from paying user charges, when using biological standards or biological preparations for public health purposes.

## PART 8—CERTIFICATION OF OPIOID TREATMENT PROGRAMS

### Subpart A—Accreditation

Sec.

- 8.1 Scope.
- 8.2 Definitions.
- 8.3 Application for approval as an accreditation body.
- 8.4 Accreditation body responsibilities.
- 8.5 Periodic evaluation of accreditation bodies.
- 8.6 Withdrawal of approval of accreditation bodies.

### Subpart B—Certification and Treatment Standards

- 8.11 Opioid treatment program certification.
- 8.12 Federal opioid treatment standards.
- 8.13 Revocation of accreditation and accreditation body approval.
- 8.14 Suspension or revocation of certification.

## 42 CFR Ch. I (10–1–12 Edition)

- 8.15 Forms.

### Subpart C—Procedures for Review of Suspension or Proposed Revocation of OTP Certification, and of Adverse Action Regarding Withdrawal of Approval of an Accreditation Body

- 8.21 Applicability.
- 8.22 Definitions.
- 8.23 Limitation on issues subject to review.
- 8.24 Specifying who represents the parties.
- 8.25 Informal review and the reviewing official's response.
- 8.26 Preparation of the review file and written arguments.
- 8.27 Opportunity for oral presentation.
- 8.28 Expedited procedures for review of immediate suspension.
- 8.29 Ex parte communications.
- 8.30 Transmission of written communications by reviewing official and calculation of deadlines.
- 8.31 Authority and responsibilities of the reviewing official.
- 8.32 Administrative record.
- 8.33 Written decision.
- 8.34 Court review of final administrative action; exhaustion of administrative remedies.

AUTHORITY: 21 U.S.C. 823; 42 U.S.C. 257a, 290aa(d), 290dd-2, 300x-23, 300x-27(a), 300y-11.

SOURCE: 66 FR 4090, Jan. 17, 2001, unless otherwise noted.

### Subpart A—Accreditation

#### §8.1 Scope.

The regulations in this part establish the procedures by which the Secretary of Health and Human Services (the Secretary) will determine whether a practitioner is qualified under section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) to dispense opioid drugs in the treatment of opioid addiction. These regulations also establish the Secretary's standards regarding the appropriate quantities of opioid drugs that may be provided for unsupervised use by individuals undergoing such treatment (21 U.S.C. 823(g)(1)). Under these regulations, a practitioner who intends to dispense opioid drugs in the treatment of opioid addiction must first obtain from the Secretary or by delegation, from the Administrator, Substance Abuse and Mental Health Services Administration (SAMHSA), a certification that the practitioner is

qualified under the Secretary's standards and will comply with such standards. Eligibility for certification will depend upon the practitioner obtaining accreditation from an accreditation body that has been approved by SAMHSA. These regulations establish the procedures whereby an entity can apply to become an approved accreditation body. This part also establishes requirements and general standards for accreditation bodies to ensure that practitioners are consistently evaluated for compliance with the Secretary's standards for opiate addiction treatment with an opioid agonist treatment medication.

### § 8.2 Definitions.

The following definitions apply to this part:

*Accreditation* means the process of review and acceptance by an accreditation body.

*Accreditation body* means a body that has been approved by SAMHSA under § 8.3 to accredit opioid treatment programs using opioid agonist treatment medications.

*Accreditation body application* means the application filed with SAMHSA for purposes of obtaining approval as an accreditation body, as described in § 8.3(b).

*Accreditation elements* mean the elements or standards that are developed and adopted by an accreditation body and approved by SAMHSA.

*Accreditation survey* means an onsite review and evaluation of an opioid treatment program by an accreditation body for the purpose of determining compliance with the Federal opioid treatment standards described in § 8.12.

*Accredited opioid treatment program* means an opioid treatment program that is the subject of a current, valid accreditation from an accreditation body approved by SAMHSA under § 8.3(d).

*Certification* means the process by which SAMHSA determines that an opioid treatment program is qualified to provide opioid treatment under the Federal opioid treatment standards.

*Certification application* means the application filed by an opioid treatment program for purposes of obtaining cer-

tification from SAMHSA, as described in § 8.11(b).

*Certified opioid treatment program* means an opioid treatment program that is the subject of a current, valid certification under § 8.11.

*Comprehensive maintenance treatment* is maintenance treatment provided in conjunction with a comprehensive range of appropriate medical and rehabilitative services.

*Detoxification treatment* means the dispensing of an opioid agonist treatment medication in decreasing doses to an individual to alleviate adverse physical or psychological effects incident to withdrawal from the continuous or sustained use of an opioid drug and as a method of bringing the individual to a drug-free state within such period.

*Federal opioid treatment standards* means the standards established by the Secretary in § 8.12 that are used to determine whether an opioid treatment program is qualified to engage in opioid treatment. The Federal opioid treatment standards established in § 8.12 also include the standards established by the Secretary regarding the quantities of opioid drugs which may be provided for unsupervised use.

*For-cause inspection* means an inspection of an opioid treatment program by the Secretary, or by an accreditation body, that may be operating in violation of Federal opioid treatment standards, may be providing substandard treatment, or may be serving as a possible source of diverted medications.

*Interim maintenance treatment* means maintenance treatment provided in conjunction with appropriate medical services while a patient is awaiting transfer to a program that provides comprehensive maintenance treatment.

*Long-term detoxification treatment* means detoxification treatment for a period more than 30 days but not in excess of 180 days.

*Maintenance treatment* means the dispensing of an opioid agonist treatment medication at stable dosage levels for a period in excess of 21 days in the treatment of an individual for opioid addiction.